Holen Sie sich die Stockscreener-App
0.00
100.00%
-41.03
Apellis Pharmaceuticals Inc Aktie (APLS) Neueste Nachrichten
Biogen projects $164M hit to Q2 results from R&D deals and acquisitions - MSN
Biogen trims Apellis pipeline and R&D team after $5.6bn takeover - MSN
Price to earnings forward of Apellis Pharmaceuticals, Inc. – LS:A2JAAW - TradingView
Biogen scales back Apellis programs, trims research roles after $5.6 billion buyout - MSN
Apellis Pharmaceuticals, Inc. Actuals & Estimates (LS:A2JAAW) - TradingView
A2JAAW Forecast — Price Target — Prediction for 2027 - TradingView
How Apellis Pharmaceuticals Inc. (APLS) Affects Rotational Strategy Timing - Stock Traders Daily
Apellis Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Sullivan Timothy Eugene - Moomoo
Apellis Pharmaceuticals Inc (APLS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
BIIB Stock: Biogen Strengthens Immunology Pipeline In Up To $1B RayThera Deal - Yahoo Finance
Apellis Pharmaceuticals Inc (APLS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Apellis Pharmaceuticals Inc (APLS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Apellis Pharmaceuticals Inc (APLS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
EBIT per share of Apellis Pharmaceuticals, Inc. – LS:A2JAAW - TradingView
Apellis Pharmaceuticals, Inc. (APLS) tops Q1 earnings and revenue estimates - MSN
Biogen (NASDAQ: BIIB) deems Apellis acquisition not significant - Stock Titan
Apellis Pharmaceuticals | SC TO-C: Written communication relating to an issuer or third party tender offer - Moomoo
Apellis Pharmaceuticals (APLS) moves 135.4% higher: Will this strength last? - MSN
Apellis (APLS) Amendment: Morgan Stanley Reports - Stock Titan
Number of shareholders of Apellis Pharmaceuticals, Inc. – BX:APLS - TradingView
APLS Technical Analysis & Stock Price Forecast - Intellectia AI
JP Morgan Maintains Apellis Pharmaceuticals (APLS) Overweight Recommendation - MSN
Biotech Growth Trust Portfolio Company Apellis To Be Acquired By Biogen - DirectorsTalk Interviews
[15-12G] Apellis Pharmaceuticals, Inc. SEC Filing - Stock Titan
Apellis soars on Biogen deal as biopharma index trails the market - BioWorld News
Biogen lands two fast-growing drugs in blockbuster Apellis deal - MSN
Apellis Pharmaceuticals (APLS) Surges 5.8%: Is This an Indication of Further Gains? - Eastern Progress
Apellis Shares Disappear After Biogen’s $5.6 Billion Buy—One Play Left - TechStock²
Apellis Pharmaceuticals (NASDAQ:APLS) Shines in Navellier’s Growth Screen With Strong Earnings and Revenue Momentum - ChartMill
Biogen’s Apellis Deal And Alzheimer’s Trial Shift Focus Beyond Price - Yahoo Finance
Biogen completes acquisition of Apellis Pharmaceuticals - Ophthalmology Times
ViaSat, Innovative Solutions & Support, and Apellis Pharmaceuticals Lead Stock Performance - Markets Mojo
Apellis Pharmaceuticals, Inc.Common Stock (NQ: APLS - FinancialContent
Biogen to acquire Apellis for $5.6B to strengthen immunology portfolio - MSN
APLS Suspended by Cantor Fitzgerald -- Rating Remains Neutral - GuruFocus
Biogen Expands Complement Disease Portfolio Through Acquisition of Apellis Pharmaceuticals - BioPharm International
Biogen upgraded to Hold after Apellis acquisition boosts prospects despite challenges. - Pluang
Biogen: Apellis Acquisition, Alzheimer's Fail Sums Up Mixed Investment Opportunity (BIIB) - Seeking Alpha
Biogen Closes Apellis Deal; APLS Leaves Nasdaq As $5.6 Billion Rare-Disease Bet Begins - TechStock²
Deep Track (APLS) reports 4.53M shares, a 3.55% stake - Stock Titan
RTW Investments, Roderick Wong report 3.69M shares in Apellis (APLS) - Stock Titan
Biogen completes $5.3B Apellis Pharmaceuticals acquisition - Yahoo Finance
Biogen Completes Acquisition of Apellis Pharmaceuticals - Sahm
Biogen stock (US09062X1037): $5.3 billion Apellis takeover reshapes growth story - AD HOC NEWS
Biogen Acquires Apellis Pharmaceuticals (APLS) to Enhance Growth Potential - GuruFocus
Apellis (NASDAQ: APLS) director tenders shares for $41 cash plus CVR - Stock Titan
Biogen deal: Apellis (APLS) VP tenders 65,955 shares, options cancelled - Stock Titan
Apellis (NASDAQ: APLS) director cashes out shares and options in Biogen tender offer - Stock Titan
Apellis (APLS) R&D chief converts stock and options to cash and CVRs in Biogen merger - Stock Titan
[Form 4] Apellis Pharmaceuticals, Inc. Insider Trading Activity - Stock Titan
1.17%
2.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):